Novel biomarker for the prediction of tamoxifen treatment in ER positive breast cancer
| Project/Area Number |
22591442
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAYASHIDA Tetsu 慶應義塾大学, 医学部, 助教 (80327543)
TAKAHASHI Maiko 慶應義塾大学, 医学部, 助教 (50348661)
SAKATA Michio 慶應義塾大学, 医学部, 助教 (60235158)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | BTG2 / 乳癌 / 内分泌療法 / 薬剤感受性 / タモキシフェン |
|---|
| Research Abstract |
Based on previous results, we analyzed if BTG2 expression affects the sensitivity against tamoxifen. Tetracycline-inducible BTG2 expression model in MCF7 was developed to assess the cytotoxicity by tamoxifen treatment in vitro and in vivo. Tumor growth ra
|
Report
(4 results)
Research Products
(8 results)
